Autoimmune Cytopenia and BcR Inhibitors (CABRI)

Institut Paoli-Calmettes

Status: Unknown

Conditions: Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia

Treatments: Drug: ibrutinib ou idelalisib

Study type: Observational

Funder types: Other

Identifiers

NCT03469895

CABRI-IPC 2017-025

Details and patient eligibility

About

Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)

Full description

The investigators of the study propose a card of data collection, validated by the scientific council of the group FILO.

The data to be collected are entered on an e-CRF made available to the investigators on a secure site.

The main data collected are as follows

• anonymized demographic data
• Clinical and Biological Data of CLL at Diagnosis
• Previous treatments of LLC and CAI
• clinical and laboratory data at the time of initiation of BCRi treatment
• response to treatment with BCRi
• tolerance to BCRi treatment
• Progression under treatment with BCRi
• Recent news

Enrollment: 40 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with CLL
• Active autoimmune cytopenia
• Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.

Exclusion criteria

• Other lymphoid hemopathy B
• Absence of documentation of the autoimmunity of cytopenia

Trial design

40 participants in 1 patient group

active CLL treated with ibrutinib or idelalisib for CAI

Description:

Patient with CLL Active autoimmune cytopenia Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia. The progressive nature of contemporary CAI LLC is not a criterion of exclusion.

Treatment:

Drug: ibrutinib ou idelalisib